🟢 CLRO is trading 20.2% up today extending gains from its Cortigent reverse-merger agreement

CLRO is trading 20.2% up at $7.79 in pre-market, extending last week’s explosive move following its merger agreement with Cortigent.

• The reverse-merger with Cortigent, a Vivani Medical subsidiary, will rename the company Cortigent Holdings, Inc. and pivot the business into the brain-computer interface and neurostimulation sectors.
• Under the terms of the deal, Vivani will own approximately 59–68% of the combined entity, while legacy CLRO holders will be diluted to an estimated 13–14% stake.